Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITAGORE: Piperacillin-tazobactam and temocillin as carbapenem alternatives in ESBL infections in ICU
2024-511866-36-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in sepsis, septic shock, extended-spectrum beta-lactamase-producing Enterobacterales infection and 1 more comparing Meropenem arm, Piperacillin-tazobactam arm and Temocillin arm (3 arms). Primary endpoint: 30-day mortality. Planned start Sep 2024; status: authorised.
02
Drugs
piperacillin + tazobactamtemocillinmeropenem
03
Conditions
sepsisseptic shockextended-spectrum beta-lactamase-producing Enterobacterales infectionGram-negative bacterial infection
Beyond the preview
Go deeper on 2024-511866-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511866-36-00.